Spironolactone & Appetite Changes: What Women With PCOS and Hormonal Acne Need to Know

Does Spironolactone Actually Change Appetite or Cravings?

Spironolactone is not a weight-loss drug, and it is not marketed as an appetite suppressant. What it does, reliably, is block aldosterone receptors and reduce circulating androgens. Both of those actions have downstream effects on how your body handles salt, fluid, insulin, and potentially food-seeking behavior. Women taking it for PCOS or hormonal acne often report eating less salty food, wanting fewer refined carbohydrates, and in some cases losing a small amount of weight without intentional dieting. Whether that reflects genuine appetite modulation or simply a reduction in androgen-driven metabolic dysregulation is a question the literature has not yet fully answered.

What the Cochrane Data Actually Shows

The most rigorous summary of spironolactone in PCOS comes from the Cochrane review of anti-androgens published in 2015, which pooled randomized controlled trials comparing anti-androgen treatments against placebo or active comparators in women with PCOS. The review found that spironolactone produced a statistically significant reduction in modified Ferriman-Gallwey hirsutism scores compared with placebo, confirming its anti-androgen efficacy. Body weight and metabolic outcomes were reported inconsistently across trials, and no dedicated appetite endpoint was measured. This is an evidence gap you deserve to know about: the appetite and craving changes women describe in clinical practice have not been the primary outcome of any powered RCT as of mid-2025.

What "Androgen Suppression" Has to Do With Food Cravings

Androgens, especially testosterone and DHEA-S, influence dopaminergic reward pathways in ways that may increase preference for calorie-dense, high-salt, and high-carbohydrate foods. Research published in Psychoneuroendocrinology found that androgen receptor signaling modulates mesolimbic dopamine activity, a circuit central to food-reward motivation. Women with PCOS, who carry supraphysiologic androgen levels, commonly report intense cravings for processed carbohydrates and salty snacks. When spironolactone reduces free testosterone by blocking peripheral androgen receptors and modestly lowering circulating androgens, the downstream dampening of food-reward signaling could explain reduced cravings. This is a biologically plausible mechanism, not a confirmed causal chain.

The Aldosterone Angle

Aldosterone itself plays a role in salt appetite. The brain contains mineralocorticoid receptors in regions including the nucleus of the solitary tract and the amygdala, areas involved in both salt-appetite regulation and broader reward processing. Animal data and small human studies suggest that mineralocorticoid receptor activation increases preference for high-sodium foods. Blocking aldosterone with spironolactone could reduce that preference. Whether the doses used clinically (50-200 mg/day) produce enough central mineralocorticoid receptor occupancy to alter food preference in women is not established by controlled human data, but the physiology is consistent with what patients report.

How Spironolactone Works: Sex-Specific Pharmacology

Spironolactone's actions in women differ from those in men in ways that matter for understanding appetite effects.

Androgen Receptor Blockade in Women

In women, circulating testosterone is primarily produced by the ovaries and adrenal glands. PCOS amplifies ovarian androgen output. Spironolactone binds competitively to androgen receptors with moderate affinity, reducing androgenic stimulation in target tissues including skin, hair follicles, and potentially the brain. This is why it treats hirsutism and hormonal acne effectively, and why it may secondarily reduce androgen-driven food-reward behavior.

Aldosterone Blockade and Fluid Dynamics

Spironolactone's primary pharmacological action is blocking the mineralocorticoid receptor, which increases urinary sodium excretion and retains potassium. Women typically carry more adipose tissue than men, and adipose tissue is a significant source of aldosterone. Higher adiposity is associated with elevated aldosterone levels, which may explain why women with obesity and PCOS sometimes notice more pronounced diuretic and appetite effects when starting spironolactone.

Pharmacokinetics in Women

Spironolactone is rapidly absorbed and converted to active metabolites, principally canrenone and 7-alpha-spirolactone. Women show higher peak plasma concentrations than men at equivalent doses, likely due to differences in body composition and cytochrome P450 activity. This means the clinical effects, including side effects like dizziness, breast tenderness, and menstrual irregularity, may appear at lower doses in women than in historical male-centric trials. Dose titration should start at 25-50 mg/day and increase slowly.

Life-Stage Guide: How Appetite Effects May Vary

Reproductive Years (Ages 18-40, Non-Pregnant)

This is the life stage where spironolactone is most commonly prescribed and most studied for appetite-adjacent effects. Women with PCOS in their 20s and 30s often describe a noticeable reduction in carbohydrate and salt cravings within 4-8 weeks of reaching a therapeutic dose (typically 100-150 mg/day for PCOS). Menstrual cycles may become more regular as androgens fall, and with that regularization, premenstrual cravings tied to luteal-phase hormonal surges may diminish. PCOS affects 8-13% of women of reproductive age worldwide and is one of the most common reasons spironolactone is prescribed off-label in this group.

Cycle-phase effects matter here. Appetite fluctuates across the menstrual cycle, with caloric intake typically rising by approximately 200-400 kcal per day in the luteal phase compared with the follicular phase, driven by progesterone and possibly estrogen withdrawal. If spironolactone regularizes cycles and attenuates the androgen spike that often accompanies the luteal phase in PCOS, some of that cyclical craving amplification may diminish.

Trying to Conceive

Stop spironolactone before attempting pregnancy. This is not optional. Reliable contraception is required while taking spironolactone if there is any possibility of pregnancy. Discuss transition planning with your prescriber at least one to two menstrual cycles before attempting conception. During the trying-to-conceive window, appetite management needs to shift to approaches compatible with pregnancy, such as inositol supplementation, which has emerging evidence from RCTs for reducing androgen-driven symptoms in PCOS without teratogenic risk.

Perimenopause (Typically Ages 45-55)

Androgen levels follow a complex trajectory in perimenopause. Testosterone does not fall as sharply as estrogen; some women experience a relative androgen excess as estrogen declines, which can worsen acne, hair thinning, and metabolic symptoms. Spironolactone is sometimes used in this life stage for those indications. The appetite-related effects described in reproductive-age women may still apply, but the data are thinner. Perimenopausal women are also more likely to be on antihypertensives or other medications with potassium-affecting profiles, so the hyperkalemia risk becomes a more active monitoring concern.

Postmenopause

In postmenopausal women, spironolactone is most often used for blood pressure control (its original FDA indication) rather than anti-androgen effects. Appetite effects in this population have not been meaningfully studied. The aldosterone-salt-appetite connection may still apply, but circulating estrogen loss changes mineralocorticoid receptor expression in ways that could modify the drug's behavioral effects. Postmenopausal women show altered aldosterone sensitivity compared with premenopausal women, which is relevant to any appetite-via-mineralocorticoid hypothesis.

Female-Relevant Conditions Where Appetite Changes Matter Most

PCOS and Metabolic Dysregulation

PCOS is not simply an ovarian condition. It is a systemic metabolic syndrome in many women, characterized by insulin resistance, compensatory hyperinsulinemia, dyslipidemia, and central adiposity. Approximately 70-80% of women with PCOS have some degree of insulin resistance, which directly amplifies carbohydrate cravings by disrupting glucose homeostasis and increasing ghrelin pulsatility. Spironolactone may modestly improve insulin sensitivity, partly by reducing androgens that impair insulin receptor signaling and partly by lowering aldosterone, which independently worsens insulin sensitivity. That metabolic improvement, even if modest, could translate to reduced postprandial crashes and fewer intense carbohydrate cravings.

A practical clinical framework: think of spironolactone's appetite effect in PCOS as operating through three overlapping channels, androgen receptor blockade reducing food-reward signaling, aldosterone blockade reducing salt appetite, and secondary insulin-sensitivity improvement reducing reactive hypoglycemia-driven cravings. No single channel has been isolated in a controlled study, but each is biologically supported. Prescribers and patients should calibrate expectations accordingly.

Hormonal Acne

Women prescribed spironolactone for hormonal acne (chin/jaw breakouts, cyclical flares) are often in their late 20s to early 40s and may not carry a PCOS diagnosis. The appetite effects, if any, in this group likely reflect anti-androgen action alone, without the metabolic insulin-resistance component that amplifies the effect in PCOS. Anecdotal reports from this population are more mixed: some women notice mild appetite reduction, many notice nothing beyond the intended skin benefit.

Female Pattern Hair Loss

Spironolactone is sometimes used off-label for androgenetic alopecia in women. The doses used (50-100 mg/day) are at the lower end of the anti-androgen range. Any appetite or craving effect is likely attenuated compared with the 150-200 mg/day doses used for PCOS hirsutism.

Pregnancy, Lactation, and Contraception: Required Reading

Spironolactone is contraindicated in pregnancy. This is not a theoretical concern. Spironolactone and its metabolites cross the placenta and block androgen receptors in the developing fetus. In animal studies, spironolactone caused feminization of male rat fetuses at doses comparable to clinical human exposure. The FDA product labeling warns against use in pregnancy and the drug should be classified as equivalent to former Category C/D with significant teratogenic concern for male fetuses.

There is no established safe dose in pregnancy.

What You Must Do Before Starting

• Confirm you are not pregnant before the first dose.
• Use highly effective contraception (combined oral contraceptive pill, IUD, implant) throughout treatment if you are of reproductive potential.
• ACOG guidance on teratogen counseling recommends that prescribers discuss contraception requirements explicitly before initiating teratogenic drugs.

Many clinicians co-prescribe a combined oral contraceptive pill (OCP) with spironolactone for women in reproductive years. The OCP adds contraceptive protection and provides ethinyl estradiol, which suppresses ovarian androgen production, creating an additive anti-androgen effect for PCOS and acne. This combination has a long track record, though it is not without its own cardiovascular and thromboembolic considerations.

Lactation

Spironolactone passes into breast milk. Studies show that canrenone, the primary active metabolite, is detectable in human milk at concentrations that could be clinically significant in a breastfeeding infant. The drug is generally avoided during lactation. If spironolactone is needed postpartum for a compelling indication (for example, severe acne or refractory blood pressure), the prescriber and patient should weigh the risks, and consultation with a lactation medicine specialist is appropriate. Transition back to spironolactone after weaning requires updated contraception confirmation before resuming.

Stopping Spironolactone to Conceive

Spironolactone should be discontinued at least one full menstrual cycle, and ideally two, before attempting conception. Its half-life is short (approximately 1.4 hours for the parent compound, though active metabolites persist longer), so physiological clearance is relatively quick, but allowing cycle normalization before conception attempts is reasonable practice.

Side Effects Women Report Most Often: Appetite and Beyond

Most appetite-adjacent side effects with spironolactone are mild and dose-dependent.

Salt Craving Reduction

This is the most biologically consistent finding. By blocking aldosterone's action on the kidney and potentially on central mineralocorticoid receptors, spironolactone reduces the physiological drive to consume sodium. For women who previously craved salty snacks heavily, this can feel like a meaningful dietary shift.

Nausea and Early Appetite Suppression

Nausea is a recognized side effect of spironolactone, particularly in the first 2-4 weeks and when taken on an empty stomach. Product labeling lists gastrointestinal disturbances including nausea, vomiting, and gastric bleeding as side effects. Early appetite suppression from nausea should be distinguished from the longer-term craving changes described above. Take spironolactone with food to reduce nausea.

Breast Tenderness

Spironolactone has mild progestogenic and anti-androgenic properties that can cause breast tenderness and, rarely, breast enlargement. This is not appetite-related but is among the most common complaints in women under 40.

Menstrual Changes

Irregular periods, spotting, or heavier bleeding occur in a meaningful proportion of women, especially at doses above 100 mg/day. These menstrual changes are relevant to appetite because luteal-phase cravings are tied to progesterone and estrogen fluctuations. Disrupted cycle architecture may either worsen or improve cyclical craving patterns depending on the individual hormonal profile.

Hyperkalemia

Potassium retention is the most clinically significant metabolic side effect. The risk is elevated in women with chronic kidney disease, those on ACE inhibitors or ARBs, and those consuming high-potassium diets (including high fruit intake, common in women trying to eat healthfully). Serum potassium should be checked at baseline, at 4 weeks after dose initiation or changes, and then periodically. Avoid potassium supplements and salt substitutes containing potassium chloride.

Who This Is Right For, and Who Should Avoid It

Good Candidates

• Women with PCOS and documented hyperandrogenism (elevated free or total testosterone) who have not achieved adequate symptom control with OCP alone.
• Women with hormonal acne, particularly chin/jaw distribution, cyclical pattern, or inadequacy of prior topical treatments.
• Women with FPHL (female pattern hair loss) in whom androgen excess is suspected and who do not wish to become pregnant.
• Perimenopausal women with persistent androgenic symptoms (acne, hirsutism) who have completed childbearing.

Not a Good Fit

• Women actively trying to conceive or who decline reliable contraception.
• Women who are pregnant or breastfeeding.
• Women with chronic kidney disease stage 3b or worse (eGFR < 45 mL/min/1.73m²), due to hyperkalemia risk.
• Women with Addison's disease or other conditions causing baseline hyperkalemia.
• Women on concurrent potassium-sparing diuretics or high-dose potassium supplementation without close monitoring.

What to Expect: A Realistic Timeline

Week 1-2: Nausea possible, especially without food. Increased urination from diuretic effect. No meaningful change in cravings yet.

Week 3-6: Salt cravings may begin to diminish. Early androgen suppression starts, though acne and hirsutism improvements lag further behind.

Month 2-4: Carbohydrate cravings may reduce noticeably in women with PCOS, paralleling improvements in fasting insulin and free testosterone. This is the window where metabolic changes become measurable.

Month 4-6: Hirsutism scores improve; the Cochrane review found significant improvement in Ferriman-Gallwey scores within 6 months. Acne response typically peaks around month 3.

Beyond 6 months: Effects on appetite and cravings, if they occur, tend to stabilize. Continued monitoring of potassium and blood pressure remains necessary.

The Evidence Gap: What We Do Not Know Yet

Women have been historically under-represented in clinical trials measuring metabolic and appetite outcomes. The appetite and craving changes described in this article are supported by plausible physiological mechanisms and consistent patient reports, but no dedicated RCT has measured appetite or craving scores as a primary endpoint in women taking spironolactone for PCOS or acne. Most of what is known comes from secondary endpoints in metabolic studies, case series, and patient-reported outcomes in observational data.

The 2015 Cochrane review explicitly noted that metabolic outcome reporting across included trials was heterogeneous and often poorly powered. Until a properly designed study measures appetite endpoints prospectively in women taking spironolactone, clinical guidance on this topic will remain extrapolated rather than directly evidence-based. Ask your prescriber to frame any appetite-related expectations accordingly.